FDA Maintained Clinical Hold on Newron Study

The U.S. clinical hold prevents new patient enrollment for Newron’s ENIGMA-TRS 2 Alzheimer’s study.

Updated on Sept. 25, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a glass vial against a cream background, representing scientific regulatory oversight. — The Food and Drug Administration has confirmed that a clinical hold on new patient enrollment for Newron’s ENIGMA-TRS 2 Alzheimer’s study remains in effect in the U.S. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to maintain rigorous safety standards during the drug development process?

The Food and Drug Administration has confirmed that a clinical hold on new patient enrollment for the Phase 3 ENIGMA-TRS 2 study remains in effect in the United States. While the trial continues to expand in other regions, no U.S. patients have yet been dosed with the study treatment.

Why it matters

The hold was initiated following an unexpected death of a participant at a non-U.S. clinical site, necessitating further regulatory review of the study protocol. The FDA intends to ensure all safety parameters are met before allowing new participants in the U.S. to enroll.

Approximately 80 patients have entered global screening for the ENIGMA-TRS 2 trial, which has a minimum enrollment target of 400 patients. Meanwhile, the concurrent ENIGMA-TRS 1 study continues across 20 countries with a target of 600 participants.

The players

Food and Drug Administration

The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products and pharmaceutical trials.

Newron

A biopharmaceutical company headquartered in Milan, Italy, that focuses on the development of novel therapies for patients with diseases of the central nervous system.

The details

Newron reported that an independent safety monitoring board recommended continuing the studies after determining the participant death was unrelated to the study drug. The company is now awaiting written communication from the FDA regarding necessary protocol adjustments to address the agency's requirements.

December 2025: The ENIGMA-TRS 2 study was initiated in the United States.
April 29, 2026: The FDA officially initiated the clinical hold on U.S. enrollment.
September 25, 2026: Newron announced the FDA hold remains in place.
Mid-October 2026: Expected enrollment of 600 patients in the ENIGMA-TRS 1 study.
Q1 2027: Expected announcement of primary endpoint results from ENIGMA-TRS 1.

The Big Picture

The FDA hold on the ENIGMA-TRS 2 Phase 3 clinical trial underscores the rigorous regulatory oversight applied to international drug development programs. This case demonstrates how safety protocols in global trials remain subject to domestic scrutiny even when adverse events occur outside of U.S. borders.

Patients and clinicians in the United States will face a temporary delay in access to the ENIGMA-TRS 2 trial until the FDA clears the current safety concerns. Prospective participants should consult with their healthcare providers regarding the status of local enrollment sites.

The takeaway

Maintaining strict adherence to international safety monitoring is a standard requirement for drug approval processes in the U.S. Patients awaiting new therapeutic options should note that regulatory delays are often precautionary measures designed to ensure long-term participant safety.